Key Takeaways
- Health Canada authorized 16 new prescription drugs and 33 generic and biosimilar drugs during the third quarter of 2026.
- The regulator approved 540 new medical devices during the same period.
- A proposed pediatric drug review approach could reduce certain review timelines from 300 days to 180 days.
Health Canada Authorizes 49 Medicines and 540 Medical Devices in Quarterly Update
Getting a medicine approved is only one step toward improving healthcare, but regulatory delays can affect how quickly new treatment options reach patients. Health Canada’s latest quarterly update highlights new authorizations alongside efforts to make reviews more efficient without lowering safety standards.
New Medicines and Medical Devices Approved
In its October 15, 2026, update, Health Canada reported authorizing 16 new prescription drugs and 33 generic and biosimilar drugs between July 1 and September 30. The department also approved 540 new medical devices during the quarter.
Health Canada also said it is prioritizing reviews of certain generic drug submissions. The goal is to improve access, reduce the risk of supply disruptions and make the review system more sustainable as submissions become more numerous and complex.
Faster Reviews for Certain Children’s Medicines
Another proposed change focuses on medicines intended for children and young people. Health Canada is consulting on an interim approach that could shorten review timelines for eligible pediatric drug submissions from 300 days to 180 days, a reduction of up to 40%.
The consultation is scheduled to close on October 23, 2026. Although the approach remains subject to the consultation process, Health Canada said it has already begun implementing shortened review timelines and welcomes additional comments on further improvements.
The department is also advancing clinical-trial modernization, including a portal to help patients and researchers find information about trials approved by Health Canada. It is also launching a pilot for Access Consortium work-sharing submissions, which it says will provide more flexibility during reviews and help prevent delays.
TwikUp’s Perspective
The update highlights a central regulatory challenge: speeding up access while preserving confidence in medicine quality and safety. Health Canada says the changes are intended to improve access while maintaining standards for safety, efficacy and quality.
For patients and families, the pediatric proposal is especially worth watching because children are often prescribed drugs intended for adults off label, meaning outside their indicated use. The consultation deadline offers stakeholders an opportunity to comment before the approach is finalized.
The next meaningful measure will be whether these changes reduce delays in practice while maintaining the evidence and safeguards required for safe treatment.